# A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

> **NCT03059615** · PHASE2 · WITHDRAWN · sponsor: **Immune System Key Ltd**

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Nerofe
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT03059615
- **Lead sponsor:** Immune System Key Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-25
- **Primary completion:** 2020-07-26
- **Final completion:** 2020-07-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No recruitment since initiation
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03059615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03059615, "A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03059615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*